Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Eleonora Cocco, Alberto Caoci, Lorena Lorefice & Maria Giovanna Marrosu. (2017) Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics 17:2, pages 173-180.
Read now
Read now
Guy R Simpson, Kate Relph, Kevin Harrington, Alan Melcher & Hardev Pandha. (2016) Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virotherapy 5, pages 1-13.
Read now
Read now
Stanley Cohan. (2016) Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics: Targets and Therapy 10, pages 119-138.
Read now
Read now
Iwona Cicha, Laura Scheffler, Astrid Ebenau, Stefan Lyer, Christoph Alexiou & Margarete Goppelt-Struebe. (2016) Mitoxantrone-loaded superparamagnetic iron oxide nanoparticles as drug carriers for cancer therapy: Uptake and toxicity in primary human tubular epithelial cells. Nanotoxicology 10:5, pages 557-566.
Read now
Read now
Articles from other publishers (26)
Zeinab Jan, Samaneh Mollazadeh, Khalil Abnous, Seyed Mohammad Taghdisi, Abolghasem Danesh, Mohammad Ramezani & Mona Alibolandi. (2022) Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics 19:7, pages 1952-1976.
Crossref
Crossref
Lindsey R. Hayes & Petr Kalab. (2022) Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics 19:4, pages 1061-1084.
Crossref
Crossref
Dhananjay Yadav, Ji Yeon Lee, Nidhi Puranik, Pallavi S. Chauhan, Vishal Chavda, Jun-O. Jin & Peter C. W. Lee. (2022) Modulating the Ubiquitin–Proteasome System: A Therapeutic Strategy for Autoimmune Diseases. Cells 11:7, pages 1093.
Crossref
Crossref
Bo Yang, Xiande Wang, Dong Dong, Yunqing Pan, Junhua Wu & Jianjian Liu. (2022) Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs
as a New a Approach. Letters in Drug Design & Discovery 19:1, pages 31-43.
Crossref
Crossref
Monica Marta, David Baker, Paul Creeke, Gareth Pryce, Sharmilee Gnanapavan & Gavin Giovannoni. (2021) Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders 56, pages 103284.
Crossref
Crossref
Daniel Rapp, Sebastian Michels, Jakob Schöpe, Lukas Schwingshackl, Hayrettin Tumani & Makbule Senel. (2021) Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies. Multiple Sclerosis and Related Disorders 56, pages 103279.
Crossref
Crossref
Miroslav Turjap & Olga Nedopílková. (2021) Treatment of multiple sclerosis from the pharmacist´s perspective. Praktické lékárenství 17:3, pages e03-e14.
Crossref
Crossref
Xin-Wen Xie, Zhao-Peng Liu & Xun Li. (2020) Design, synthesis, bioevaluation of LFC- and PA-tethered anthraquinone analogues of mitoxantrone. Bioorganic Chemistry 101, pages 104005.
Crossref
Crossref
Dhiraj Kumar, Rashmi K. Ambasta & Pravir Kumar. (2020) Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies. Ageing Research Reviews 61, pages 101078.
Crossref
Crossref
Qian-Wen LI, Wen LEI, Cong CHEN & Wei GUO. (2020) Recent advances of long noncoding RNAs involved in the development of multiple sclerosis. Chinese Journal of Natural Medicines 18:1, pages 36-46.
Crossref
Crossref
Paulus S. Rommer, Ron Milo, May H. Han, Sammita Satyanarayan, Johann Sellner, Larissa Hauer, Zsolt Illes, Clemens Warnke, Sarah Laurent, Martin S. Weber, Yinan Zhang & Olaf Stuve. (2019) Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology 10.
Crossref
Crossref
Paulus S. Rommer, Michael Hecker, Tobias Zrzavy, Nina Boxberger & Uwe K. Zettl. 2019. Neuroimmune Diseases. Neuroimmune Diseases
387
421
.
Serena Ruggieri, Simona Pontecorvo, Carla Tortorella & Claudio Gasperini. (2018) Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Multiple Sclerosis and Demyelinating Disorders 3:1.
Crossref
Crossref
J. Frau, G. Coghe, P. Casanova, C. Sardu, L. Lorefice, G. Fenu, M. G. Marrosu & E. Cocco. (2018) Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. European Journal of Neurology 25:8, pages 1063-1068.
Crossref
Crossref
Justine L. DelgadoChao-Ming Hsieh, Nei-Li Chan & Hiroshi Hiasa. (2018) Topoisomerases as anticancer targets. Biochemical Journal 475:2, pages 373-398.
Crossref
Crossref
Grace Gombolay & Tanuja Chitnis. 2018. Neuroinflammation. Neuroinflammation
277
294
.
Paolo Ragonese, Paolo Aridon, Sabrina Realmuto, Giulia Vazzoler, Simona Alessi, Erika Portera, Alessia Bianchi, Fabio Triolo, Maria Antonietta Mazzola, Marco D?Amelio, Giovanni Savettieri & Giuseppe Salemi. (2017) Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort study. Multiple Sclerosis and Demyelinating Disorders 2:1.
Crossref
Crossref
Venkat Subramaniam, Gin Chuang, Huijing Xia, Brendan Burn, Jessica Bradley, Jerome L. Maderdrut, David H. Coy & Kurt J. Varner. (2017) Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. Peptides 95, pages 25-32.
Crossref
Crossref
A. García Merino, J.R. Ara Callizo, O. Fernández Fernández, L. Landete Pascual, E. Moral Torres & A. Rodríguez-Antigüedad Zarrantz. (2017) Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurología (English Edition) 32:2, pages 113-119.
Crossref
Crossref
A. García Merino, J.R. Ara Callizo, O. Fernández Fernández, L. Landete Pascual, E. Moral Torres & A. Rodríguez-Antigüedad Zarrantz. (2017) Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología. Neurología 32:2, pages 113-119.
Crossref
Crossref
. (2016) Reduce the risk of adverse events associated with disease-modifying therapies for multiple sclerosis by following appropriate mitigation strategies. Drugs & Therapy Perspectives 32:5, pages 197-202.
Crossref
Crossref
Maira Gironi, Caterina Arnò, Giancarlo Comi, Giselle Penton-Rol & Roberto Furlan. 2016. Immune Rebalancing. Immune Rebalancing
63
84
.
Marzio Pennisi, Giulia Russo, Santo Motta & Francesco Pappalardo. (2015) Agent based modeling of the effects of potential treatments over the blood–brain barrier in multiple sclerosis. Journal of Immunological Methods 427, pages 6-12.
Crossref
Crossref
Adnan M. Subei & Daniel Ontaneda. (2015) Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs 29:9, pages 759-771.
Crossref
Crossref
Jan Dörr & Friedemann Paul. (2015) The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology 17:6.
Crossref
Crossref
Alberto Gajofatto & Maria Donata Benedetti. (2015) Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. World Journal of Clinical Cases 3:7, pages 545.
Crossref
Crossref